Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine

Goadsby, 2017, Pathophysiology of Migraine: A Disorder of Sensory Processing, Physiol Rev, 97, 553, 10.1152/physrev.00034.2015 Buse, 2010, Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers, J Neurol Neurosurg Psychiatry, 81, 428, 10.1136/jnnp.2009.192492 2017, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, 1211, 10.1016/S0140-6736(17)32154-2 Headache Classification Committee of the International Headache Society (IHS), 2018, The International Classification of Headache Disorders, 3rd edition, Cephalalgia, 38, 1, 10.1177/0333102417738202 Natoli, 2010, Global prevalence of chronic migraine: a systematic review, Cephalalgia., 30, 599, 10.1111/j.1468-2982.2009.01941.x Bigal, 2008, Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study, Headache., 48, 1157, 10.1111/j.1526-4610.2008.01217.x Buse, 2019, Migraine Progression: A Systematic Review, Headache., 59, 306, 10.1111/head.13459 Lipton, 2015, Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine, Neurology., 84, 688, 10.1212/WNL.0000000000001256 Edvinsson, 2005, Neurobiology in primary headaches, Brain Res Brain Res Rev, 48, 438, 10.1016/j.brainresrev.2004.09.007 Edvinsson, 1995, Neuropeptides in the cerebral circulation: relevance to headache, Cephalalgia., 15, 272, 10.1046/j.1468-2982.1995.1504272.x Schytz, 2010, The PACAP receptor: a novel target for migraine treatment, Neurotherapeutics., 7, 191, 10.1016/j.nurt.2010.02.003 Ferrari, 2002, Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials, Cephalalgia., 22, 633, 10.1046/j.1468-2982.2002.00404.x Lipton, 2019, Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study, Headache., 59, 1310, 10.1111/head.13588 Dodick, 2004, Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine, Headache., 44, 414, 10.1111/j.1526-4610.2004.04078.x Bigal, 2009, The acute treatment of episodic and chronic migraine in the USA, Cephalalgia., 29, 891, 10.1111/j.1468-2982.2008.01819.x American Headache S, 2019, The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice, Headache., 59, 1, 10.1111/head.13456 Diener, 2019, Pathophysiology, prevention, and treatment of medication overuse headache, Lancet Neurol, 18, 891, 10.1016/S1474-4422(19)30146-2 Hay, 2018, Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25, Br J Pharmacol, 175, 3, 10.1111/bph.14075 Amara, 1982, Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products, Nature., 298, 240, 10.1038/298240a0 Rubio-Beltran, 2020, Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries, Cephalalgia., 40, 357, 10.1177/0333102419884943 Kawasaki, 1988, Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat, Nature., 335, 164, 10.1038/335164a0 Gulbenkian, 1993, Peptidergic innervation of human epicardial coronary arteries, Circ Res, 73, 579, 10.1161/01.RES.73.3.579 Chan, 2010, Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries, J Pharmacol Exp Ther, 334, 746, 10.1124/jpet.110.165993 Edvinsson, 2019, Recognizing the role of CGRP and CGRP receptors in migraine and its treatment, Cephalalgia., 39, 366, 10.1177/0333102417736900 Storer, 2004, Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat, Br J Pharmacol, 142, 1171, 10.1038/sj.bjp.0705807 Summ, 2010, Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus, Brain., 133, 2540, 10.1093/brain/awq224 Russo, 2015, Calcitonin gene-related peptide (CGRP): a new target for migraine, Annu Rev Pharmacol Toxicol, 55, 533, 10.1146/annurev-pharmtox-010814-124701 Walker, 2018, CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured, Cephalalgia., 38, 437, 10.1177/0333102417691762 McLatchie, 1998, RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, Nature., 393, 333, 10.1038/30666 Moore, 2012, Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine, Br J Pharmacol, 166, 66, 10.1111/j.1476-5381.2011.01633.x Christopoulos, 1999, Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product, Mol Pharmacol, 56, 235, 10.1124/mol.56.1.235 Lauritzen, 1994, Pathophysiology of the migraine aura. The spreading depression theory, Brain., 117, 199, 10.1093/brain/117.1.199 Close, 2019, Cortical spreading depression as a site of origin for migraine: Role of CGRP, Cephalalgia., 39, 428, 10.1177/0333102418774299 Goadsby, 1988, Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system, Ann Neurol, 23, 193, 10.1002/ana.410230214 Goadsby, 1993, The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats, Ann Neurol, 33, 48, 10.1002/ana.410330109 Lassen, 2002, CGRP may play a causative role in migraine, Cephalalgia., 22, 54, 10.1046/j.1468-2982.2002.00310.x Chiba, 1989, Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37), Am J Phys, 256, E331 Doods, 2000, Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist, Br J Pharmacol, 129, 420, 10.1038/sj.bjp.0703110 Moreno-Ajona, 2019, Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review, Headache., 59, 3, 10.1111/head.13582 Olesen, 2004, Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine, N Engl J Med, 350, 1104, 10.1056/NEJMoa030505 Xu, 2019, Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine, Front Pharmacol, 10, 795, 10.3389/fphar.2019.00795 Paone, 2007, J Med Chem, 50, 5564, 10.1021/jm070668p Ho, 2008, Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine, Neurology., 70, 1304, 10.1212/01.WNL.0000286940.29755.61 Connor, 2009, Randomized, controlled trial of telcagepant for the acute treatment of migraine, Neurology., 73, 970, 10.1212/WNL.0b013e3181b87942 Ho, 2008, Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial, Lancet., 372, 2115, 10.1016/S0140-6736(08)61626-8 Hewitt, 2011, Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine, Headache., 51, 533, 10.1111/j.1526-4610.2011.01860.x Piaggio, 2012, Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement, JAMA., 308, 2594, 10.1001/jama.2012.87802 Behm, 2011, Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study, Headache., 51, 954, 10.1111/j.1526-4610.2011.01901.x Ho, 2012, Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease, Headache., 52, 224, 10.1111/j.1526-4610.2011.02052.x Chaitman, 2012, A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina, Clin Pharmacol Ther, 91, 459, 10.1038/clpt.2011.246 Ho, 2014, Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention, Neurology., 83, 958, 10.1212/WNL.0000000000000771 Ho, 2016, Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine, Cephalalgia., 36, 148, 10.1177/0333102415584308 Diener, 2011, BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study, Cephalalgia., 31, 573, 10.1177/0333102410388435 Hewitt, 2011, Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine, Cephalalgia., 31, 712, 10.1177/0333102411398399 Luo, 2012, J Med Chem, 55, 10644, 10.1021/jm3013147 Moore, 2020, Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin GeneRelated Peptide Receptor, J Pharmacol Exp Ther, 10.1124/jpet.119.261065 Goadsby, 2019, Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study, 92 Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, the First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine [press release]. New Haven, CT: Biohaven Pharmaceuticals; Published December 17, 2019 (accessed 1 March 2020) 2020 Croop, 2018, A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant in healthy adult subjects under fasting conditions, Headache, 58, 1287 Lipton, 2019, Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine, N Engl J Med, 381, 142, 10.1056/NEJMoa1811090 Tong, 2013, Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects, J Headache Pain, 14, P118, 10.1186/1129-2377-14-S1-P118 Hall, 2005, A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials, Contemp Clin Trials, 26, 349, 10.1016/j.cct.2005.02.001 Marcus, 2014, BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial, Cephalalgia, 34, 114, 10.1177/0333102413500727 Lipton, 2018, RIMEGEPANT 75 MG, AN ORAL CALCITONIN GENE-RELATED PEPTIDE ANTAGONIST, FOR THE ACUTE TREATMENT OF MIGRAINE: TWO PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIALS, Cephalalgia, 38, 18 Tfelt-Hansen, 2012, Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators, Cephalalgia, 32, 6, 10.1177/0333102411417901 Croop, 2019, Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial, Lancet, 394, 737, 10.1016/S0140-6736(19)31606-X Drug Trials Snapshots: NURTEC ODT https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-nurtec-odt Approval date: 27 February (accessed 1 March 2020) Lipton, 2019, Long-term, open-label safety study of rimegepant 75 mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy, Cephalalgia, 39, 189 Biohaven presents data demonstrating reduction in migraine-related disability and improvement in patient reported outcomes after oral treatment with rimegepant at the international headache conference late breaking session [press release]. New Haven, CT: Biohaven Pharmaceuticals; Published September 9, 2019. https://www.biohavenpharma.com/investors/news-events/press-releases/09-09-2019 (accessed 30 March 2020) Voss, 2016, A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine, Cephalalgia, 36, 887, 10.1177/0333102416653233 Dodick, 2019, Ubrogepant for the Treatment of Migraine, N Engl J Med, 381, 2230, 10.1056/NEJMoa1813049 Lipton, 2019, Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial, JAMA, 322, 1887, 10.1001/jama.2019.16711 Ailani, 2019, An Optional Second Dose of Ubrogepant Is Effective in Achieving 2- Hour Pain Freedom in the Acute Treatment of Migraine, Headache, 59, 98 Ferrari, 1994, Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences, Cephalalgia, 14, 330, 10.1046/j.1468-2982.1994.1405330.x Goadsby, 2019, Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults, Cephalalgia, 39, 1753, 10.1177/0333102419869918 Ailani, 2019, Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine, Neurology (Minneap), 92 Scott, 2020, Ubrogepant: First Approval, Drugs, 80, 323, 10.1007/s40265-020-01264-5 Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM et al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-y l)-4-(2-oxo-1,2-dihydroquinolin-3-yl) piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett 2013;23(11):3157-61. doi:https://doi.org/10.1016/j.bmcl.2013.04.012. Biohaven to advance vazegepant into phase 3 for the acute treatment of migraine following successful end of phase 2 meeting with FDA. [press release]. New Haven CBP. (accessed 30 March 2020) Brand, 1987, Placebo controlled study of a selective 5-HT1-Like agonist, AH25086B, in relief of acute migraine, Cephalalgia, 7, 402, 10.1177/03331024870070S6176 Doenicke, 1988, Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine, Lancet, 1, 1309, 10.1016/S0140-6736(88)92122-8 Dodick, 2019, CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications, Cephalalgia, 39, 445, 10.1177/0333102418821662 Goadsby, 2017, A Controlled Trial of Erenumab for Episodic Migraine, 377, 2123 Dodick, 2018, ARISE: A Phase 3 randomized trial of erenumab for episodic migraine, Cephalalgia, 38, 1026, 10.1177/0333102418759786 Tepper, 2017, Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial, Lancet Neurol, 16, 425, 10.1016/S1474-4422(17)30083-2 Reuter, 2018, Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study, Lancet, 392, 2280, 10.1016/S0140-6736(18)32534-0 Tepper, 2019, Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial, Neurology, 92, e2309, 10.1212/WNL.0000000000007497 Mullin, 2019, Successful Gepant-Monoclonal Antibody Combination: Rimegepant 75mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab, Cephalalgia, 39, 192 Kielbasa, 2019, A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody, Cephalalgia, 39, 1284, 10.1177/0333102419840780 Vandenbussche, 2018, Medication-overuse headache: a widely recognized entity amidst ongoing debate, J Headache Pain, 19, 50, 10.1186/s10194-018-0875-x Lai, 2018, Neuroimaging Findings in Patients with Medication Overuse Headache, Curr Pain Headache Rep, 22, 1, 10.1007/s11916-018-0661-0 Aurora, 2019, Medication Overuse in a Post-hoc Analysis of Phase 3 Placebo-controlled Studies of Galcanezumab in the Prevention of Episodic and Chronic Migraine, Headache, 59, 23 Silberstein, 2019, The impact of fremanezumab on medication overuse in patients with chronic migraine, Neurology (Minneap), 95